Prot #CA2350001: Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination with Azacitidine and in Triple Combination with Azacitidine and Venetoclax in Subjects with Relapsed or Refractory Acu

Project: Research project

Project Details

StatusActive
Effective start/end date7/24/25 → 7/24/28

Funding

  • Bristol-Myers Squibb Company (Prot #CA2350001)